{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:30:25Z","timestamp":1778236225789,"version":"3.51.4"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Cetuximab was shown in phase III clinical trials to improve chemotherapy efficacy in patients with advanced colorectal and head-neck cancer. Appropriate management of skin reactions associated with epidermal growth factor receptor inhibitor therapy is necessary to allow adequate drug compliance and to improve patient quality of life and outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The RAND\/UCLA Appropriateness Method was used by a group of experts to produce new Italian recommendations on the management of skin reactions in this setting. Statements were generated on the basis of an updated systematic review of the literature and rated twice by a panel of 38 expert physicians. A meeting of the panel was held after the first rating session.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Skin reactions included acneiformic rash, skin dryness (xerosis), pruritus, paronychia, hair abnormalities, mucositis, and increased growth of eyelashes or facial hair. Updates of the previous recommendations on the prevention and treatment of each type of reaction were proposed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This updated Expert Opinion focuses on how to assess and correctly grade skin reactions according to the latest National Cancer Institute Common Terminology Criteria for Adverse Events and on how to manage these adverse events in clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000291","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T17:36:31Z","timestamp":1461087391000},"page":"407-415","source":"Crossref","is-referenced-by-count":27,"title":["Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy"],"prefix":"10.1097","volume":"39","author":[{"given":"Carmine","family":"Pinto","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Clinical Cancer Centre, IRCCS-Arcispedale S. Maria Nuova, Reggio Emilia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo A.","family":"Barone","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Universit\u00e0 Cattolica Sacro Cuore, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Dermatology, University of Verona, Verona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvio G.","family":"Russi","sequence":"additional","affiliation":[{"name":"Radiotherapy Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco C.","family":"Merlano","sequence":"additional","affiliation":[{"name":"Oncology Unit, Santa Croce and Carle Hospital, Cuneo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daris","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Oncology Unit, San Paolo Hospital, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[{"name":"Oncology Unit, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230905","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-20230905","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutations status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"R3-20230905","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"R4-20230905","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann Oncol"},{"key":"R5-20230905","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial","volume":"10","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"R6-20230905","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-20230905","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"R8-20230905","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"R9-20230905","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"R10-20230905","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R11-20230905","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitor","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R12-20230905","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R13-20230905","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00204-014-1244-4","article-title":"Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors","volume":"88","author":"Pastore","year":"2014","journal-title":"Arch Toxicol"},{"key":"R14-20230905","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.ejca.2010.03.008","article-title":"Interobserver agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study","volume":"46","author":"Duffour","year":"2010","journal-title":"Eur J Cancer"},{"key":"R16-20230905","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2008.16.9391","article-title":"Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib","volume":"26","author":"Braiteh","year":"2008","journal-title":"J Clin Oncol"},{"key":"R17-20230905","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"R18-20230905","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"R19-20230905","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.138.1.129","article-title":"Follicular toxic effects of chimeric antiepidermal growth factor receptor antibody cetuximab used to treat human solid tumors","volume":"138","author":"Kimyai-Asadi","year":"2002","journal-title":"Arch Dermatol"},{"key":"R20-20230905","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"R21-20230905","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with none small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"R22-20230905","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","article-title":"Nail toxicity associated with epidermal growth factor receptor inhibitor therapy","volume":"56","author":"Fox","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"18S","key":"R23-20230905","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1200\/jco.2007.25.18_suppl.9127","article-title":"Influence of skin color in the development of erlotinib-induced rash: a report from the SERIES clinic","volume":"25","author":"Lai","year":"2007","journal-title":"J Clin Oncol"},{"key":"R24-20230905","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/tpj.2011.51","article-title":"Pharmacogenetic predictors for anti-EGFR inhibitor associated skin toxicity","volume":"13","author":"Parmar","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"R26-20230905","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cbpa.2009.03.021","article-title":"The therapeutic potential of phosphatase inhibitors","volume":"13","author":"Vintonyak","year":"2009","journal-title":"Curr Opin Chem Biol"},{"key":"R27-20230905","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2478\/v10019-008-0022-4","article-title":"Management of cutaneous side effects of cetuximab therapy with vitamin K1 creme","volume":"42","author":"Ocvirk","year":"2008","journal-title":"Radiol Oncol"},{"issue":"suppl 7","key":"R28-20230905","first-page":"vii 22","article-title":"Topical application of vitamin K1 cream for cetuximab-related skin toxicities","volume":"20","author":"Ocvirk","year":"2009","journal-title":"Ann Oncol"},{"key":"R29-20230905","doi-asserted-by":"crossref","first-page":"abstr e19671","DOI":"10.1200\/jco.2010.28.15_suppl.e19671","article-title":"Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash","volume":"suppl","author":"Radovics","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"R30-20230905","first-page":"vi24","article-title":"Prophylactic use of vitamin K1 cream for the reduction of skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (MCRC)","volume":"21","author":"Ocvirk","year":"2010","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"R31-20230905","first-page":"v123","article-title":"Management of skin rash with topical vitamin K1 during anti-EGFR monoclonal antibody treatment (Italian Observational Study)","volume":"22","author":"Pinto","year":"2011","journal-title":"Ann Oncol"},{"key":"R32-20230905","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1468-3083.2011.04324.x","article-title":"Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis","volume":"27","author":"Tomkov\u00e1","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R33-20230905","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1684\/ejd.2012.1899","article-title":"Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer","volume":"23","author":"Jo","year":"2013","journal-title":"Eur J Dermatol"},{"key":"R34-20230905","doi-asserted-by":"crossref","first-page":"abstr e14600","DOI":"10.1200\/jco.2014.32.15_suppl.e14600","article-title":"Italian observational study in patients with metastatic colorectal cancer (mCRC) treated with first-line cetuximab based regimen (ObservEr study)","volume":"suppl","author":"Di Fabio","year":"2014","journal-title":"J Clin Oncol"},{"key":"R35-20230905","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clcc.2013.10.001","article-title":"Pilot clinical trial on the efficacy of prophylactic use of Vitamin K1- based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer","volume":"13","author":"Pinta","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"R36-20230905","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000017847","article-title":"Systemic antibiotics for acne","volume":"196","author":"Meynadier","year":"1998","journal-title":"Dermatology"},{"key":"R37-20230905","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"R38-20230905","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"R39-20230905","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00520-010-0988-5","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)","volume":"19","author":"Jatoi","year":"2011","journal-title":"Support Care Cancer"},{"key":"R40-20230905","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00520-012-1715-1","article-title":"Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study","volume":"21","author":"Grande","year":"2013","journal-title":"Support Care Cancer"},{"key":"R41-20230905","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/jdv.12365","article-title":"Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash","volume":"28","author":"Vaubel","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R42-20230905","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","article-title":"Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy","volume":"16","author":"Pinto","year":"2011","journal-title":"Oncologist"},{"key":"R43-20230905","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Ann Oncol"},{"key":"R44-20230905","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/annonc\/mdr139","article-title":"Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines","volume":"22","author":"Bernier","year":"2011","journal-title":"Ann Oncol"},{"key":"R45-20230905","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000355579","article-title":"Management of \u2018in-field\u2019 skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy","volume":"85","author":"Cante","year":"2013","journal-title":"Oncology"},{"key":"R46-20230905","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"suppl.","key":"R47-20230905","doi-asserted-by":"crossref","first-page":"abstr 6090","DOI":"10.1200\/jco.2014.32.15_suppl.6090","article-title":"Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC)","volume":"32","author":"Ferris","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl.","key":"R48-20230905","doi-asserted-by":"crossref","first-page":"abstr 6005","DOI":"10.1200\/jco.2014.32.15_suppl.6005","article-title":"Final analysis: a randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN)","volume":"32","author":"Harrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"R49-20230905","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/annonc\/mdt281","article-title":"Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191-2200","volume":"24","author":"Russi","year":"2013","journal-title":"Ann Oncol"},{"key":"R50-20230905","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00520-011-1324-4","article-title":"The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy","volume":"20","author":"Russi","year":"2012","journal-title":"Support Care Cancer"},{"key":"R51-20230905","doi-asserted-by":"crossref","first-page":"518261","DOI":"10.1155\/2014\/518261","article-title":"Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation","volume":"2014","author":"Russi","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R52-20230905","first-page":"abstr 3036","article-title":"Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin","volume":"24","author":"Perez-Soler","year":"2006","journal-title":"ASCO Annual Meeting Proc"},{"key":"R53-20230905","first-page":"abstr 9124","article-title":"Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib in human keratinocytes whereas Vit K3 exerts a protective effect: implications for the management of skin rash","volume":"25","author":"Perez-Soler","year":"2007","journal-title":"ASCO Annual Meeting Proc"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201608000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T23:37:35Z","timestamp":1693957055000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201608000-00015"}},"subtitle":["Update of the Italian Expert Recommendations"],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000291","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}